Global News

Trial Registries Proliferate: Is Anyone Benefiting?

Wednesday, August 2, 2006

The issue of clinical trial result transparency continues to evolve at a rapid pace. During the past few years, almost every stakeholder has taken action in some form.  This should be a positive development because there is a lot attention being focused on a very important issue. But at the end of the day, have we made a difference? Has the noise that this caused just confused the issue more for patients and physicians, or made finding trial information easier and more useful?

[Read More]

New Medical Device CRO Symbios Clinical Established

Monday, July 31, 2006

Symbios Clinical, a new contract research organization (CRO) based in Minnesota, has recently begun formal operations. The CRO focuses on the medical device industry. The company began with $500,000 in start-up financing. Co-founders Ethan Rooney and Ryan Wilson began the company after careers in the medical device sector, both working for large companies. During an interview conducted by CenterWatch, Ethan Rooney elaborated on the need for such a CRO in the medical device industry:

[Read More]

Super-Size The FDA

Friday, July 21, 2006

A proposal in Congress to boost funding for the FDA makes a lot of sense. But don’t stop there, Congress – a super-sized FDA would help solve many of the issues around drug safety. Make sure it’s truly independent, though, and free from pressures from the pharmaceutical industry, brought upon it by a lack of resources. Drug research reformists often suggest creating an independent clinical trials agency to perform trials for the industry, but that’s a far-fetched and unworkable solution.

[Read More]

Averion Goes Public

Wednesday, July 19, 2006

The San Diego, Calif.-based company IT&E International, a regulatory compliance and validation services provider has agreed to merge with Averion, a contract research organization based in Framingham, Mass., for roughly $25 million, including $20 million of stock and notes and $5 million in cash. The new company will retain the Averion name, and allow Averion to become a publicly traded company.

[Read More]